Researchers are urging collaborators to think about the best structural resolution for their formulation models.

The data published in NEJM highlight the positive Phase 3 VALIANT results at Week 26, which were consistent across adolescent and adult patients with C3G and primary IC-MPGN, including patients with ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the latest findings on time savings with continued treatment with humanized anti-soluble ...